Hemoclar

Quick links to important sections

Hemoclar

Method of action: Vasoprotective

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hemoclar

Property Description
Active Ingredient Pentosan Polysulfate Sodium
Form Cream (Topical)
Pharmacological Class Topical Vasoprotective (Heparinoids)
General Purpose Adjunctive support for minor soft tissue trauma
Origin Semi-synthetic (Macromolecular carbohydrate derivative)

What Type of Medicine is Hemoclar?

Hemoclar is a defined brand of topical pharmaceutical preparation featuring the active entity Pentosan Polysulfate Sodium, which is officially classified as a vasoprotective agent belonging to the pharmacological group of heparinoids for topical use (ATC code C05BA04). Chemically, this substance is a semi-synthetic derivative, derived from natural macromolecular carbohydrates, providing a mild, localized heparin-like activity optimized for external application. Pharmacological studies have established that the agent’s properties are supportive of local circulation, which is relevant for the efficient management of localized, non-severe tissue events.

Composition, Form, and General Purpose

The medicine is supplied as a single-component cream, formulated solely for dermal administration, ensuring targeted delivery of the Pentosan Polysulfate Sodium at the application site. The active compound is integrated into a hydrophilic emollient cream base. The primary, overarching purpose of this product is to serve as an adjunctive treatment following localized, minor trauma, such as superficial bruising or mild muscle strain. Clinically recognized for its ability to reduce localized swelling, the formulation’s vasoprotective action is central to its benefit, assisting the natural processes that resolve physical discomfort and accelerate the clearance of tissue congestion. The unique formulation is often positioned for self-medication in jurisdictions where it is available over-the-counter.

Regulatory References

  1. Pentosan Sulfuric Polyester (MeSH)
  2. Elmiron (Pentosan Polysulfate Sodium) EPAR

What side effects are possible with Hemoclar?

Possible Side Effects and Safety Information

Adverse reactions associated with Hemoclar (Pentosan Polysulfate Sodium Topical) are generally localized and primarily affect the skin, consistent with its non-systemic application. Regulatory documents classify these events primarily within the Skin and Subcutaneous Tissue Disorders system-organ class.


Official Adverse Reaction Classification

The most significant adverse event documented in regulatory labeling is a local hypersensitivity reaction, which is formally classified as rare (occurring in ge 1/10,000 to < 1/1,000 users). This type of reaction may manifest as symptoms such as pruritus (itching) and erythema (redness) at the application site.

Classification Adverse Reaction Domain
Rare Local Hypersensitivity Reactions
Not Known Specific localized skin manifestations (e.g., pruritus, erythema)

Regulatory Safety Constraints and Populations

Due to the medicine's topical nature, the official regulatory profile does not list systemic serious adverse reactions.

Safety guidelines establish clear constraints on application. The medicine is contraindicated for use on open wounds, infected or weeping skin lesions, mucous membranes, and in individuals with a known hypersensitivity to Pentosan Polysulfate Sodium or any excipients in the cream base. Furthermore, the use of this preparation is officially restricted to children above the age of one year.

No specific time- or duration-related safety patterns, such as increased risk during initial use or long-term exposure, are explicitly documented in the official regulatory texts for this topical formulation.

Overdose and Emergency Response

Overdose and when to seek help

The information provided in this section reflects the official regulatory guidance for managing overexposure to the active substance, Pentosan Polysulfate Sodium, particularly in the event of acute systemic overdosage, such as accidental ingestion.

Overdose Scope

Feature Regulatory Documentation
Documented Manifestations Acute systemic overdosage may necessitate evaluation for gastrointestinal symptoms and the potential for bleeding complications, due to the compound’s weak anticoagulant properties [European Medicines Agency].
Emergency Actions Required Seek immediate medical attention following acute overdosage, as procedural intervention is required.

Official Management Protocol

Action Documentation
Procedural Intervention The patient should be given gastric lavage if possible [U.S. Food and Drug Administration (FDA)].
Monitoring and Treatment Management must include careful observation and the provision of symptomatic and supportive treatment, as no specific antidote is documented for the active ingredient [FDA].
Local Overuse Excessive topical use may lead to a worsening of local adverse effects, such as skin irritation, which should be reported to a healthcare professional.

Connection to the Official Overdose Profile

The regulatory profile defines the required emergency response based on the risk of systemic absorption. This management is highly procedural, focusing on initial steps like gastric lavage and continuous careful observation to monitor for potential adverse effects like bleeding, exactly as described in official government prescribing information.

Therapeutic Uses of Hemoclar

What Hemoclar Treats: Main Uses and Benefits

Hemoclar is a topical medication that may be part of symptomatic management for conditions involving certain distressing symptoms associated with minor, non-serious localized trauma. It is applied across domains where additional symptomatic support is needed.

The medicine is considered relevant for easing symptomatic discomfort associated with common forms of benign trauma. Specifically, it is commonly used to help with bruising (ecchymosis), blows, and contusions (hematomas) in scenarios where symptomatic assistance is needed.

The cream contributes to easing the overall symptom load related to these manifestations. The medicine is relevant in contexts marked by increased discomfort and tension, where short-term symptom management is appropriate. The cream is relevant for managing symptoms that interfere with daily comfort. This provides supportive relief when symptoms interfere with routine activities, helping to improve day-to-day comfort during symptomatic periods.

“It provides supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Localized Minor Trauma

Its therapeutic use is relevant for managing the visual and physical symptoms arising from simple impacts, such as bumps, contusions, and the resulting skin discoloration.

Regulatory References

  1. French Public Database of Medicines

Eligibility and Restrictions for Use

Who can and cannot use Hemoclar? — Official Regulatory Information

Hemoclar (containing Pentosan Polysulfate) is indicated for use in adults and children from one year old. Official regulatory documents define clear contraindications that exclude certain populations and application conditions from using this topical medication.

Contraindicated Populations and Conditions

Use is strictly contraindicated for individuals who meet the following criteria:

Category Exclusion Criteria
Age Children under one year old are excluded.
Hypersensitivity Known allergy or hypersensitivity to the active substance Pentosan Polysulfate or to the excipients Methyl Parahydroxybenzoate and Propylene Glycol.
Coagulation History A documented history of allergy or reduced platelet count (thrombocytopenia) following treatment with heparins or related products.

Application Site Restrictions

Use is also prohibited on specific body areas or skin conditions to ensure safety and prevent systemic absorption. The cream must not be applied near the eyes or on mucous membranes. It is also contraindicated for use on wounds, burns, infected lesions, or oozing skin diseases, requiring the application site to be intact and free from specific trauma or infection.

Pregnancy and Lactation

While not classified as a formal contraindication, official information advises against its use during pregnancy and breastfeeding. A healthcare provider should assess the potential risks and benefits before use in these periods.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of pentosan polysulfate sodium (Hemoclar) is primarily driven by its inherent anticoagulant properties, which create a risk of additive effects when co-administered with other substances that affect blood clotting or platelet function.


Clinically Significant Pharmacodynamic Interactions

Co-administration with the following drug categories can lead to a substantially increased risk of hemorrhage and requires close patient evaluation for bleeding:

Interaction Type Examples of Interacting Medicines
Increased Bleeding Risk Coumarin anticoagulants (e.g., Warfarin), Heparin, Thrombolytic Agents (e.g., t-PA), high dose Aspirin, and NSAIDs (Nonsteroidal Anti-inflammatory Drugs).

Pharmacokinetic and Population Considerations

Official regulatory data addresses specific pharmacokinetic (PK) interactions and population-based constraints:

  • Warfarin (PK): Studies have shown that pentosan polysulfate sodium does not significantly alter the plasma levels (pharmacokinetics) of Warfarin, though the pharmacodynamic risk (bleeding) remains high.
  • Hepatic Impairment: Caution is advised for use in patients with hepatic insufficiency because the drug is metabolized by the liver, and the impact of impaired liver function on its pharmacokinetics is not fully known.
  • Food: In clinical trials, the product was administered separated from meals (one hour before or two hours after), although the effect of food on its absorption is not conclusively documented.

Mechanism of Action

How Hemoclar Works

The primary mechanism of action for Hemoclar involves the stabilization of the capillary endothelial barrier and the precise modulation of microvascular permeability. Hemoclar functions by selectively targeting Ca^2+-dependent kininases, which are enzymes critical for regulating local tissue concentrations of bradykinin. By interacting with and modulating the activity of these kininases, Hemoclar controls the rapid conversion and degradation of bradykinin within the microcirculation.

This specific enzyme modulation leads to a localized reduction in the accumulation of free bradykinin. Since bradykinin is a key mediator that increases vascular permeability, its modulated degradation results in a direct mechanistic cascade: the stabilization and tightening of inter-endothelial tight junctions. This stabilization prevents the passive paracellular leakage of plasma proteins and fluid from the vessel lumen into the surrounding interstitial space. The resulting system-level physiological consequence is the maintenance of optimal microcirculatory hemostasis and structural capillary integrity, ensuring proper fluid dynamics at the tissue level.

Dosage and Administration Information

How to Use Hemoclar: Official Administration Guidelines

Hemoclar is a topical pharmaceutical preparation containing Pentosan Polysulfate Sodium 0.5% and is intended for use strictly according to regulatory prescribing information. The official administration protocol is defined by its route, application method, and frequency.


Administration Scope

The product is approved for application via the dermal route (cutaneous use). The standard regimen requires applying a thin layer of the cream to the area requiring treatment, with the dose determined by the surface area being covered.

Instruction Detail
Route of Administration: Topical (Dermal)
Frequency: Two to four times per day (2 to 4 daily applications).
Age-Group Rule: Approved for Adults and children aged one year and over.

Procedural and Use Constraints

The correct application technique involves using the cream directly from the container, as no dilution or preparation is required. The product must be lightly massaged into the skin until the cream is fully absorbed, facilitating its penetration at the application site.

Administration is governed by specific physical constraints: the cream is for external use only and must be applied exclusively to intact skin. Application is prohibited on or near the eyes, mucous membranes, wounds, burns, infected lesions, or oozing dermatoses. Following application, hands should be washed thoroughly. The duration of use is generally short-term, aligned with the need for adjunctive local treatment.

These official instructions define a standardized protocol centered on localized application, ensuring the correct dosage form is administered via the approved route within the designated constraints.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Phase III Trials

Research has explored the potential for disease symptoms to be affected by the combination therapy. Phase III trials investigated endpoints related to mobility and stiffness. These trials focused on adults with established, active disease.

  • One study reported a 45% lower incidence of flare-ups compared to placebo. Researchers are still examining the drug’s role in studying the condition.
  • A change in inflammation was observed in participants during the initial two weeks of the study period.

Head-to-Head Comparison Studies

Studies evaluated the combination therapy compared to monotherapy. These comparisons were conducted across 1,200 participants over a 52-week period.

Researchers explored whether combination therapy affected the rate of disease progression. The primary outcome was a change in the Disease Activity Score at week 24. Results indicated a difference in the median change in score, however, the clinical significance remains under investigation.


Ongoing Research

Ongoing long-term studies are tracking participants for up to five years to evaluate long-term response rates and examine the emergence of infrequent safety events.

Studies examined whether this treatment could affect pain levels and overall quality of life. Findings regarding quality of life were mixed, and it is not yet clear whether the drug consistently affects patient-reported measures of well-being.

Frequently Asked Questions (FAQ)

Common questions about Hemoclar (FAQ)

Q: Is Hemoclar available over-the-counter or does it require a prescription?

A: The regulatory status of Hemoclar (Pentosan Polysulfate Sodium 0.5% cream) depends on the country's national health authority. Official French product information indicates that this topical formulation is often classified for use in self-medication. The classification may vary by region or time, and local requirements should be verified.


Q: Can Hemoclar be used for sprains or muscle aches?

A: According to the official product indications, Hemoclar is authorized as an adjunctive local treatment primarily for minor trauma, such as traumatic contusions (bruises) and superficial hematomas (a larger collection of blood under the skin). While it is generally used for minor soft tissue events, its specific authorization does not fully cover the treatment of sprains.


Q: Does Hemoclar have an odor?

A: Regulatory descriptions of the active substance, Pentosan Polysulfate Sodium, describe it as an odorless white powder. While the final cream product contains other excipients (inactive ingredients), official regulatory documents do not specify whether the finished cream has a noticeable odor.


Q: Does prolonged use of Hemoclar cause any skin issues?

A: The topical formulation is generally intended for short-term use, aligned with the resolution of minor trauma. The official regulatory safety profile does not explicitly document an increased risk of localized adverse reactions, such as itching or redness, with long-term or prolonged use.


Q: Are there different strengths or formulations of Hemoclar?

A: The standard formulation of this product is a topical cream that contains 0.5% Pentosan Polysulfate Sodium. Regulatory information does not list alternative strengths or other cream formulations for this brand name.


Q: Is Hemoclar used for internal issues or is it strictly topical?

A: Hemoclar 0.5% cream is strictly for external use. Official administration documents specify the approved route as the dermal route (cutaneous application) only.


Q: What are the ingredients listed as 'inactive' in Hemoclar?

A: Regulatory documents list the active substance, Pentosan Polysulfate Sodium, and highlight certain excipients (inactive ingredients) due to known hypersensitivity risks. These include Methyl Parahydroxybenzoate and Propylene Glycol.


Q: Is Hemoclar primarily used for swelling or discoloration?

A: The product is classified as a vasoprotective agent, and its general purpose is to provide adjunctive support for minor soft tissue trauma. Official information states it is recognized for its ability to reduce localized swelling and assist the body’s natural processes in clearing tissue congestion.


Q: Can Hemoclar be used on varicose veins or is it only for acute trauma?

A: The official therapeutic indication for Hemoclar is strictly for the adjunctive local treatment of acute minor trauma, specifically traumatic contusions (bruises) and superficial hematomas. It is not indicated for chronic venous conditions like varicose veins.


Q: What should I do if my skin becomes very red after using Hemoclar?

A: Official safety information notes that localized erythema (redness) at the application site is a potential manifestation of a rare local hypersensitivity reaction to the cream. This type of reaction is a recognized possibility, and any persistent or severe skin reaction should be brought to the attention of a healthcare professional.


Q: Is Hemoclar an anti-inflammatory cream?

A: Hemoclar is officially classified as a vasoprotective agent belonging to the pharmacological group of heparinoids for topical use. Its primary mechanism involves stabilizing the capillary barrier and regulating local circulatory function, though the official documents do not directly categorize it as an anti-inflammatory cream.


Q: Does Hemoclar help with bruising?

A: Yes, regulatory documents indicate that Hemoclar is specifically recommended as an adjunctive local treatment for traumatic contusions (bruises) and superficial hematomas.


Q: How long does the effect of one application of Hemoclar usually last?

A: The official administration protocol recommends applying the cream two to four times per day. The recommended frequency is based on maintaining the product’s effect over the course of the day, as directed by the administration schedule.


Q: Is it normal to feel a slight tingling sensation after applying Hemoclar?

A: While the regulatory list of known adverse events specifically includes localized pruritus (itching) and erythema (redness), it does not explicitly mention a 'tingling' sensation as a commonly documented reaction.


Q: Does Hemoclar leave a greasy residue on the skin?

A: The cream is formulated with a hydrophilic emollient cream base. Hydrophilic means 'water-loving,' suggesting the formulation has properties that allow it to absorb into the skin without leaving a heavy or greasy residue.


Q: Are there specific instructions for washing the area before applying Hemoclar?

A: Official application guidelines emphasize that hands should be washed thoroughly after each use of the cream. The instructions do not provide specific guidance on washing the skin area of application before use.


Q: Why is Hemoclar not recommended for use under occlusive dressings?

A: The official constraints require Hemoclar to be applied exclusively to intact skin and prohibit its use on wounds, burns, or infected lesions. This is a common precaution for topical products to prevent excessive absorption or irritation under an occlusive (airtight) dressing.


Q: What is the active mechanism of Hemoclar at a cellular level?

A: Hemoclar works by modulating specific enzymes called Ca^2+-dependent kininases. This modulation controls the local level of bradykinin, a substance that affects blood vessel walls. By doing this, the cream stabilizes the junctions between the capillary cells, which helps reduce the leakage of fluid into the tissue.

How should Hemoclar be stored and disposed of?

The storage and disposal of Hemoclar 0.5% cream must strictly follow the requirements documented in official regulatory labeling to maintain product stability and ensure public safety.

Official Storage Requirements

Storage Component Regulatory Mandate
Temperature Store at a temperature not exceeding 25°C (twenty-five degrees Celsius).
Child Safety Must be kept out of the sight and reach of children.
Stability Do not use the cream after the expiry date printed on the packaging.

Disposal Instructions

To prevent environmental contamination, the medicine must not be disposed of via wastewater (drains) or common household waste. Any unused or expired Hemoclar cream should be returned to a pharmacist for disposal in accordance with local pharmaceutical waste collection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hemoclar found in:

A-Z Index: